HLT Meridian Valve CE Mark Trial

NATerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 12, 2019

Primary Completion Date

September 20, 2019

Study Completion Date

September 20, 2019

Conditions
Aortic Valve Stenosis
Interventions
DEVICE

HLT® Transcatheter System

Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).

Trial Locations (1)

G1V 4G5

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HLT Inc.

INDUSTRY

NCT03805711 - HLT Meridian Valve CE Mark Trial | Biotech Hunter | Biotech Hunter